may delay consideration of a bill until next month. Eli Lilly lost 3.3 percent to $34.16. King Pharmaceuticals Inc.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
KING PHARMACEUTICALS (KG)
King Pharmaceuticals, Inc. is the world’s 39th-largest pharmaceutical company. It provides branded prescription pharmaceutical products worldwide It primarily offers branded prescription products for primary care physicians, neurologists, orthopedic surgeons, hospitals, internal medicine physicians, allergists, pediatricians, and pain specialists. Some brands include Altace for heart attack prevention; Levoxyl for hypothyroidism; Sonata for sleeping; and Skelaxin, a muscle relaxant.
King Pharmaceuticals (KG) is part of Business Exchange, suggested by
Ginny Moore.
This topic contains
133 news
and
95 blog
items.
Read updated news, blogs, and resources about King Pharmaceuticals (KG). Find user-submitted articles and reactions on King Pharmaceuticals (KG) from
like-minded professionals.
News
Please add new articles to this topic
Acurox is a formulation of niacin and the generic pain killer oxycodone. The product was being co-developed with King...
Jenkins, speaking to reporters, said he could not comment on the status of any specific applications under review.
Recothrom, a synthetic protein designed to stop bleeding during surgery, avoids complications associated with another...
7. EpiCept Corporation 8. Schering Plough Corp 9. Forest Laboratories Inc 10. Mylan Inc 11. Herbalife Ltd 12.
DOW JONES NEWSWIRES King Pharmaceuticals Inc.(KG) swung to a first-quarter loss on acquisition- related costs as...
Generic drugs are hitting King Pharmaceuticals(KG Quote) where it hurts. Still, the company managed to top Wall...
King Pharmaceuticals Inc.: PharmaVitae Profile Introduction This analysis examines the historical and forecast...
commercial success is whether doctors and patients believe the increased potency outweighs the higher risk of fatal...
prior to approval. * As previously disd, regulatory responsibility for FDA approval of REMOXY was recently shifted to...
We considered past experience in the selection process,' said Avidas' McCall, the former Vice President of sales for...
BRISTOL, Tenn.--(Business Wire)-- King Pharmaceuticals, Inc. (NYSE:KG) reported today that the Company plans to...
King Pharmaceuticals was up in Wednesday after-hours trading following heavy options activity. The options action began...
estimates, citing the suspension of the development of a product by its partner. The company said its partner King...
King Pharmaceuticals (KG Quote) The options action began Wednesday morning at the $10 strikes in May, July, and...
the boom in used car sales: Carmax(KMX Quote) Najarian said he has seen strong options activity in King...
financial relationships with them. Acura's New Drug Deters Abuse Little-known Acura Pharmaceuticals (ACUR) has teamed...
82, or 10%, to 16.08 after FBR cut its rating on the broker because of 'cyclical pressures.' King Pharmaceuticals added...
Novo Nordisk A/S both dipped about 1%, while Dr. Reddy's Laboratories shares hopped 4% to $10.29. King Pharmaceuticals...
NEW YORK - Shares of King Pharmaceuticals Inc. rose Wednesday after a Goldman Sachs analyst put the stock on a...
Laboratories; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen, L.P.; Johnson & Johnson Wound Management, a...
II-6 4. Recent Industry Activity II-7 Jubilant Acquires Draxis for US$ 253 Million II-7 JHP Acquires Assets of King...
- Stock Picks) rated new Outperform at Credit Suisse following positive meeting with management. Sets $45 target price.
BRISTOL, Tenn.--(Business Wire)-- King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to provide a live webcast...
Pharmaceuticals, Inc. 163 6.2.4 Cephalon, Inc. 168 6.2.5 Eli Lilly 171 6.2.7 King Pharmaceuticals, Inc.
Top Sources: King Pharmaceuticals (KG)
- Reuters
- MarketWatch
- TheStreet.com
- CNBC
- Morningstar.com
- Wall Street Journal Online
- BusinessWeek
- Smart Money
- Motley Fool
- Reuters UK
Most Active Users in this Topic
No user contributions
account